Amicus Therapeutics, Inc.
6 Cedar Brook Drive
Cranbury,
NJ 08512
United States - Map
Phone: 609-662-2000
Fax: 609-662-2001
Web Site: http://www.amicustherapeutics.com
| Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs, known as pharmacological chaperones, for the treatment of various human genetic diseases. Pharmacological chaperones selectively bind to the target protein, increase the stability of the protein, help it fold into the three-dimensional shape, and allow proper trafficking of the protein, thereby increasing protein activity, enhance cellular function, and reduce cell stress. It is primarily targeting lysosomal storage disorders, which are severe, chronic genetic diseases. The companys products include Amigal, which has completed Phase II clinical trial for the treatment of Fabry disease; Plicera, a Phase II clinical trial product for the treatment of Gaucher disease; and AT2220, a Phase II clinical trial product for the treatment of Pompe disease. Amicus Therapeutics has a strategic collaboration with Shire Pharmaceuticals Ireland Ltd. to jointly develop three lead pharmacological chaperone compounds for lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. John F. Crowley , 41
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Matthew R. Patterson , 37
Chief Operating Officer |
N/A
| N/A | Dr. David J. Lockhart Ph.D., 47
Chief Scientific Officer |
$
429.00K |
$
0 | Dr. Jian-Qiang Fan Ph.D.,
Founder and Vice-Pres of Research |
N/A
| N/A | Dr. Robert J. Desnick M.D., Ph.D.,
Founder |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.03% Nasdaq 
0.07 (1.80%) 
Profile
